Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
about
Mouse models for filovirus infectionsStructural basis for differential neutralization of ebolavirusesEbolavirus glycoprotein structure and mechanism of entryNeglected filovirusesA whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection.Use of monoclonal antibodies against Hendra and Nipah viruses in an antigen capture ELISAEbola virus pathogenesis: implications for vaccines and therapies.Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteinsAccelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses.VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in miceEbola virus outbreaks in Africa: past and present.Passive antibody administration (immediate immunity) as a specific defense against biological weapons.Ebola virus-like particles protect from lethal Ebola virus infection.Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccinesEbola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infectionPostexposure antibody prophylaxis protects nonhuman primates from filovirus disease.Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.Progress in filovirus vaccine development: evaluating the potential for clinical use.The potential of antibody-mediated immunity in the defence against biological weapons.Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers.Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virusTreatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection.A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animalsPersistent infection with ebola virus under conditions of partial immunity.Protection against filovirus infection: virus-like particle vaccines.Replication-deficient ebolavirus as a vaccine candidate.Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primatesComparative study between Ribavirin and Ribavirin plus Intravenous Immunoglobulin against Crimean Congo hemorrhagic fever.Correlates of immunity to filovirus infection.Characterization of host immune responses in Ebola virus infections.Development of experimental and early investigational drugs for the treatment of Ebola virus infections.Small Animal Models for Studying Filovirus Pathogenesis.Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
P2860
Q27011569-9111DD7A-DDD5-4A6E-A1EA-72B87D5CA31FQ27014910-E723EC26-83B1-4C71-BA8E-83069606591BQ27490991-CFAF9541-89CA-4910-A298-07704E246E36Q28383265-9C8DFCF8-0025-4B2E-89AF-20483499DE51Q30386068-43D2A1D5-F79E-42D6-BCDF-CC7089E02FBBQ33425912-9285F680-4E13-4794-A860-81DF4E75317AQ33961230-6AAF2DF7-65B5-48D7-9EA4-2AFA36856BD4Q33967985-7C215403-81F5-43BF-BDEF-354A5509C54EQ34123838-994D17D2-9EED-4D86-A8B9-70479A6CE7E0Q34220503-0B2B6FDD-12DA-4958-8BFB-72D79C5B627BQ34345308-5038CA95-2796-414D-97E3-0667A4F35A65Q34463780-6F8A3CDA-C47B-4250-AF0C-9CC43F188C16Q34464533-2AAF7A8F-388E-4E6F-B0E6-EC7C72F34AE8Q34509643-1523B2D7-5660-42B2-AE55-D9A109D55948Q34552637-7DC10073-E321-48A9-BAD6-2F11E75FC7C3Q34762095-0BDA8F86-00E6-4C2C-AD2B-1BDC78044C85Q34792924-93B95DF0-F263-422B-AF87-9D4273DFADD8Q35635459-842F7E25-8BF9-4DA4-AA6D-1E1F8EC7653DQ35842390-C6534792-9E77-48BC-9B1B-B4B5806F35CFQ35882397-04F5ADDA-624F-4A85-A757-C0A846D1C6BCQ35955731-F43300A0-E517-44CB-9E20-A547035F37E9Q36100545-E55C55E4-89FD-4970-8865-765887473405Q36273411-903B7CD7-0C9F-4FE6-B232-51036A4F1E12Q36378625-A233B2F3-2C27-4BF7-A04C-76116F086ED1Q36379337-6AEADBD7-24BB-48C0-9278-EAF1B56D2C56Q36482804-82D60103-2CD2-43DC-BB98-2D43BE78706BQ36484103-55B15EB2-FD61-4BE3-A09D-0E6F0E04FA0AQ36789989-158C65BA-56F5-460C-96A4-77D7926A74D7Q36844471-0D8D531A-A11E-47B8-9A5E-7792BA48E256Q36942635-AB2394C3-EF9A-479F-8F51-08B79F946909Q37130463-1C5A2EC0-4383-4479-9DD9-C429F5C08863Q37145203-B2199285-45A8-44E9-8AFC-C9A45D3859DAQ37213207-128897B7-D68A-489C-9BEA-BA89A1FDF024Q37282815-38FB3059-4B23-4E81-A6BB-E64FFB215CB9Q37945233-EF5FC570-24D4-4593-BD6A-A3CECBB3A974Q38205274-68B262EC-3B60-46F9-8699-DB5C0ECA4002Q38524949-73F77FDC-FEB5-4846-9130-4D68BCE99C50Q38666317-CFC7DCD0-40A2-4A95-99AD-C8CD6877CD54Q38847348-CB469EC4-1C33-44F0-B7CA-3CCD97337CBAQ38848208-00962AAC-4608-4251-96A1-749C7D8C26FC
P2860
Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Passive transfer of antibodies ...... hibition of viral replication.
@ast
Passive transfer of antibodies ...... hibition of viral replication.
@en
type
label
Passive transfer of antibodies ...... hibition of viral replication.
@ast
Passive transfer of antibodies ...... hibition of viral replication.
@en
prefLabel
Passive transfer of antibodies ...... hibition of viral replication.
@ast
Passive transfer of antibodies ...... hibition of viral replication.
@en
P2093
P2860
P1433
P1476
Passive transfer of antibodies ...... nhibition of viral replication
@en
P2093
P2860
P304
P356
10.1128/JVI.75.10.4649-4654.2001
P577
2001-05-01T00:00:00Z